ReviewGastroenterology2024
Evolving Concepts in Helicobacter pylori Management.
Review in Gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Gastric cancer prevention byFrontiers in oncology · 2026Pooled it
- ACG Clinical Guideline: Diagnosis and Management of Gastric Premalignant Conditions.The American journal of gastroenterology · 2025Guideline
- Trial
- Efficacy and safety of triple therapy with vonoprazan forWorld journal of gastroenterology · 2025Trial
- Helicobacter pylori-Induced Persistent IGF2BP1 Activation Promotes Ferroptosis Resistance in Gastric Tumorigenesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Reframing early gastric carcinogenesis through lineage, niche, and evolution.Cancer metastasis reviews · 2026Review
- Association of Resistance-AssociatedAntibiotics (Basel, Switzerland) · 2026Article
- Beyond Urease: New Potential Enzymatic Targets inACS omega · 2026Review
- Genomic landscape and fine-scale population structure of Helicobacter pylori across China.Biomarker research · 2026Article
- Direct/enrichment dual-mode lateral flow immunoassay enabled by a composite magnetic-fluorescent nanolabel for ultrasensitive detection of Helicobacter pylori.Mikrochimica acta · 2026Article
- Efficacy and Cost-Effectiveness of Vonoprazan-Amoxicillin Dual Therapy Versus Esomeprazole-Bismuth Quadruple Therapy forMicroorganisms · 2026Article
- Multiplex fluorescent PCR-based detection of Helicobacter pylori nucleic acid and antibiotic resistance genes in clinical stool samples: a performance evaluation from Gansu Province, China.BMC infectious diseases · 2026Article
- Design and Screening of the Peptide SAMP-12aa Derived from LL-37, Which Exhibits Anti-Molecules (Basel, Switzerland) · 2026Article
- The Effects ofJournal of clinical medicine · 2026Review
- From Eradication to Holistic Regeneration: Pharmaceutics Strategies for Reshaping Gastric Homeostasis AgainstPharmaceutics · 2026Review
- Barriers toBMJ open · 2026Article
- OptimizingWorld journal of gastroenterology · 2026Article
- Epidemiological investigation and risk factors analysis of Helicobacter pylori infection in children and teenagers in Hainan Province.BMC infectious diseases · 2026Article
- Targeting ferroptosis inInternational journal of oncology · 2026Review
- Advances in the Management of RefractoryGastro hep advances · 2026Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Helicobacter pylori is the most common chronic bacterial infection worldwide and the most significant risk factor for gastric cancer, which remains a leading cause of cancer-related death globally. H pylori and gastric cancer continue to disproportionately impact racial and ethnic minority and immigrant groups in the United States. The approach to H pylori case-finding thus far has relied on opportunistic testing based on symptoms or high-risk indicators, such as racial or ethnic background and family history. However, this approach misses a substantial proportion of individuals infected with H pylori who remain at risk for gastric cancer because most infections remain clinically silent. Moreover, individuals with chronic H pylori infection are at risk for gastric preneoplastic lesions, which are also asymptomatic and only reliably diagnosed using endoscopy and biopsy. Thus, to make a significant impact in gastric cancer prevention, a systematic approach is needed to better identify individuals at highest risk of both H pylori infection and its complications, including gastric preneoplasia and cancer. The approach to H pylori eradication must also be optimized given sharply decreasing rates of successful eradication with commonly used therapies and increasing antimicrobial resistance. With growing acceptance that H pylori should be managed as an infectious disease and the increasing availability of susceptibility testing, we now have the momentum to abandon empirical therapies demonstrated to have inadequate eradication rates. Molecular-based susceptibility profiling facilitates selection of a personalized eradication regimen without necessitating an invasive procedure. An improved approach to H pylori eradication coupled with population-level programs for screening and treatment could be an effective and efficient strategy to prevent gastric cancer, especially in minority and potentially marginalized populations that bear the heaviest burden of H pylori infection and its complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.